Key statistics
On Thursday, Exelixis Inc (EXEL:NSQ) closed at 41.28, -16.81% below its 52-week high of 49.62, set on Jun 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 41.25 |
|---|---|
| High | 41.35 |
| Low | 40.48 |
| Bid | 41.00 |
| Offer | 41.50 |
| Previous close | 41.69 |
| Average volume | 3.60m |
|---|---|
| Shares outstanding | 259.71m |
| Free float | 253.96m |
| P/E (TTM) | 14.98 |
| Market cap | 10.83bn USD |
| EPS (TTM) | 2.78 USD |
Data delayed at least 15 minutes, as of Mar 05 2026 21:00 GMT.
More ▼
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
More ▼
